Abstract library

22 results for "PET-scan".
#1124 Correlation Between the 18F-FDG Uptake and Pathological Data in Well-Differentiated Digestive and Pulmonary Neuroendocrine Tumors (NET)
Introduction: The 18F-FDG uptake assessed by PET/CT is correlated to prognosis in most tumors.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Margot Bucau
#1048 The Additional Value of Somatostatin Receptor Scintigraphy During Preoperative Staging in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors.
Introduction: During diagnostic workup for non-functioning pancreatic neuroendocrine tumors (NF-pNET) both computed tomography scan (CT-scan) and somatostatin receptor scintigraphy (SRS) are made.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Anneke Jilesen
#541 Contrast-Enhanced Ultrasound (CEUS) is a Helpful Tool to Predict the Effectiveness of Somatostatin Analogues in Patients with Liver Metastases From Neuroendocrine Tumors
Introduction: Contrast-enhanced ultrasonography (CEUS) allows characterization of the micro-vascularization of tumor lesions. Liver metastases (LM) from neuroendocrine tumors (NET) show a typical pattern on CEUS, consistent with a rapid, intense and homogeneous enhancement (hypervascular pattern) in the arterial phase.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Valeria Ramundo
#1897 Prognosis of Sporadic Resected Small (≤ 2 cm) Nonfunctional Pancreatic Neuroendocrine Neoplasms - A Multi-Institutional Study
Introduction: Malignant potential of sporadic nonmetastatic nonfunctional pancreatic neuroendocrine tumors (sNF-PNET) is difficult to preoperatively predict
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Pr Sebastien Gaujoux
Keywords: pancreatic NETs
#2095 Progression of Mesenteric Metastasis in Small Intestinal Neuroendocrine Tumors
Introduction: A metastatic mesenteric mass is a hallmark of small intestinal neuroendocrine tumours (SI-NETs). However, little is known about the development of a SI-NET associated mesenteric mass over time.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Drs. Anela Blazevic
#25 Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis
Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Mazen Hassanain
#146 Recurrence characteristics in resected pulmonary typical and atypical carcinoids
Introduction: Pulmonary typical and atypical carcinoids are widely considered indolent, although they can metastasize even with a very long relapse free interval. No standard follow-up strategy exists after a radical resection.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Michela Squadroni
#256 Evaluation of the Association Between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
Introduction: Bone mineral density (BMD) and fractures are influenced by diet, activity, drugs and hormones. Recent studies highlight an inverse relationship between serotonin and BMD.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Maralyn R Druce
#398 Ileal GEP-NEN in Mother and Son – Option for Familial Disease
Introduction: Familial cases of ileal GEP-NEN have been described on some few occasions in the literature. Speculations of familial disease with or without a relationship to MEN-1 or other inherited endocrine neoplasias have been made
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Joakim Hennings
#501 FOLFOX Regimen for Clinically Aggressive Neuroendocrine Tumors: About one Case
Introduction: The treatment for progressive metastatic well-differentiated pancreatic neuroendocrine tumors is based on adriamycin and streptozotocin chemotherapy, which achieves more than 60% tumor regression. However, severe adverse effects are common.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Doctor Leïla Bengrine-Lefevre